Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenny C Yang

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/SofosbuvirCurtis Cooper, Susanna Naggie, Michael Saag, et al.
Hepatology Communications|January 8, 2020
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis BAnna S Lok, Fabien Zoulim, Geoffrey Dusheiko, et al.
Journal of Hepatology|December 22, 2023
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppressionEdward J Gane, P Rod Dunbar, Anna E Brooks, et al.
Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.
Hepatology Communications|February 7, 2018
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatmentEdward J Gane, Sophie Metivier, Ronald Nahass, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 3, 2016
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infectionJia-Horng Kao, Rong-Nan Chien, Ting-Tsung Chang, et al.
Journal of Gastroenterology and Hepatology|February 5, 2016
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virusWan-Long Chuang, Rong-Nan Chien, Cheng-Yuan Peng, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/SofosbuvirCurtis Cooper, Susanna Naggie, Michael Saag, et al.
Hepatology Communications|January 8, 2020
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis BAnna S Lok, Fabien Zoulim, Geoffrey Dusheiko, et al.
Journal of Hepatology|December 22, 2023
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppressionEdward J Gane, P Rod Dunbar, Anna E Brooks, et al.
Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.
Hepatology Communications|February 7, 2018
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatmentEdward J Gane, Sophie Metivier, Ronald Nahass, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 3, 2016
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infectionJia-Horng Kao, Rong-Nan Chien, Ting-Tsung Chang, et al.
Journal of Gastroenterology and Hepatology|February 5, 2016
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virusWan-Long Chuang, Rong-Nan Chien, Cheng-Yuan Peng, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Pageof 3